Mesoblast to acquire Angioblast and speed up stem cell work

Australia's Mesoblast is snapping up the outstanding shares of New York-based Angioblast Systems in a deal that marries their work with mesenchymal precursor cells and positions the stem cell therapy developer to launch its first marketing operation in 2012. The deal calls for Mesoblast to swap its shares for the 67 percent of Angioblast it doesn't already own. The Angioblast package comes with the IP to experimental therapies for diabetes, cardiovascular disease and eye disease, as...